Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head

Bone

Volumn 39, Issue 1, 2006, Pages 205-212

  Kim, Harry K W ^a   Sanders, Mike ^a   Athavale, Sanjay ^a   Bian, Haikuo ^a   Bauss, Frieder ^b  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Avascular necrosis; Bioavailability; Bisphosphonate; Femoral head; Ibandronate; Ischemic necrosis; Osteonecrosis

Indexed keywords

CARBON 14; IBANDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVASCULAR NECROSIS; BONE REMODELING; CONTROLLED STUDY; DISEASE COURSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; FEMUR HEAD; INFARCTION; LIQUID SCINTILLATION COUNTING; NONHUMAN; RADIOACTIVITY; REVASCULARIZATION; STATISTICAL ANALYSIS; SWINE;

ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL AVAILABILITY; BONE DENSITY CONSERVATION AGENTS; CARBON RADIOISOTOPES; DIPHOSPHONATES; FEMUR HEAD; INFARCTION; INFUSIONS, PARENTERAL; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RADIONUCLIDE IMAGING; SWINE; TIME FACTORS;

EID: 33744804800     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.12.019     Document Type: Article

References (28)

1. Agarwala S., Jain D., Joshi V.R., and Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology 44 (2005) 352-359
2. Anderson C. Radioautography. Manual for the examination of bone (1982), CRC Press, Inc., Boca Raton 73-76
3. Aronson J. Osteoarthritis of the young adult hip: etiology and treatment. In: Anderson L. (Ed). Instructional course lectures vol. 35 (1986), American Academy of Orthopaedic Surgeons, Park Ridge, Illinois 119-128
4. Astrand J., and Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet. Disord. 3 (2002) 19
5. Bauss F., and Russell R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos. Int. 15 (2004) 423-433
6. Bowers J.R., Dailiana Z.H., McCarthy E.F., and Urbaniak J.R. Drug therapy increases bone density in osteonecrosis of the femoral head in canines. J. Surg. Orthop. Adv. 13 (2004) 210-216
7. Catterall A., Pringle J., Byers P.D., Fulford G.E., Kemp H.B.S., Dolman C.L., et al. A review of the morphology of Perthes' disease. J. Bone Jt. Surg., Br. 64 (1982) 269-275
8. Cooperman D.R., Wallensten R., and Stulberg D. Post-reduction avascular necrosis in congenital dislocation of the hip. J. Bone Jt. Surg., Am. 62 (1980) 247-258
9. Endele R., Loew H., and Bauss F. Analytical methods for the quantification of ibandronate in body fluids and bone. J. Pharm. Biomed. Anal. 39 (2005) 246-256
10. Etienne G., Mont M.A., and Ragland P.S. The diagnosis and treatment of nontraumatic osteonecrosis of the femoral head. Instr. Course Lect. 53 (2004) 67-85
11. Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 19 (1998) 80-100
12. Glimcher M.J., and Kenzora J.E. The biology of osteonecrosis of the human femoral head and its clinical implications: II. The pathological changes in the femoral head as an organ and in the hip joint. Clin. Orthop. 139 (1979) 283-312
13. Herring JA. Legg-Calve-Perthes Disease. Monograph Series. Rosemont, Illinois: American Academy of Orthopaedic Surgeons; 1996.
14. Hofstaetter J., Wang J., Samuel R., and Glimcher M. The effect of alendronate in the treatment of experimental osteonecrosis. Trans. Orthop. Res. Soc. 30 (2005) 318
15. Jensen O.M., and Lauritzen J. Legg-Calve-Perthes' disease-Morphological studies in two cases examined at necropsy. J. Bone Jt. Surg., Br. 58 (1976) 332-338
16. Jones L.C., and Hungerford D.S. Osteonecrosis: etiology, diagnosis, and treatment. Curr. Opin. Rheumatol. 16 (2004) 443-449
17. Jonsater S. Coxa plana. A histo-pathologic and arthographic study. Acta Orthop. Scand., Suppl. 12 (1953) 25-54
18. Jung A., Bisaz S., and Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif. Tissue Res. 11 (1973) 269-280
19. Kim H.K., Randall T.S., Bian H., Jenkins J., Garces A., and Bauss F. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J. Bone Jt. Surg., Am. 87 (2005) 550-557
20. Kim H.K., and Su P.H. Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model. J. Bone Jt. Surg., Am. 84-A (2002) 1329-1334
21. Kim H.K.W., Su P.-H., and Qiu Y.-S. Histopathologic changes in growth plate cartilage following ischemic necrosis of the capital femoral epiphysis. J. Bone Jt. Surg., Am. 83 (2001) 688-697
22. Lai K.A., Shen W.J., Yang C.Y., Shao C.J., Hsu J.T., and Lin R.M. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J. Bone Jt. Surg., Am. 87 (2005) 2155-2159
23. Little D.G., McDonald M., Sharpe I.T., Peat R., Williams P., and McEvoy T. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. J. Orthop. Res. 23 (2005) 862-868
24. Little D.G., Peat R.A., McEvoy A., Williams P.R., Smith E.J., and Baldock P.A. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J. Bone Miner. Res. 18 (2003) 2016-2022
25. McAndrew M., and Weinstein S.L. A long-tern follow-up of Legg-Calve-Perthes disease. J. Bone Jt. Surg., Am. 66 (1984) 860-869
26. McKibbin B., Ralis Z., and Wales C. Pathological changes in a case of Perthes' disease. J. Bone Jt. Surg., Br. 56 (1974) 438-447
27. Nishii T., Sugano N., Miki H., Takao M., Koyama T., Hashimoto J., et al. Alendronate treatment for prevention of collapse development in patients with osteonecrosis of the femoral head. Trans. Orthop. Res. Soc. 29 (2004) 153
28. Pringle D., Koob T.J., and Kim H.K. Indentation properties of growing femoral head following ischemic necrosis. J. Orthop. Res. 22 (2004) 122-130